Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights that the price adjustment of Laopu Gold exceeded expectations, reinforcing its high-end brand positioning. The price increase for most products is concentrated in the range of 20% to 30%, significantly higher than previous adjustments [5][27]. - The report emphasizes the shift in consumer demand towards self-wearing and aesthetic-driven purchases, suggesting that brands with differentiated product capabilities are likely to navigate price increases more smoothly [31][33]. Summary by Sections Industry Trends - The retail and social service indices reported a decline of 1.64% and an increase of 1.68% respectively during the week from February 24 to February 27, 2026. The retail index ranked 30th among 31 primary industries [7][16]. - The jewelry sector has shown the highest growth, with a year-to-date increase of 10.59% [19]. Investment Recommendations - Investment Theme 1: Focus on high-end gold and fashion jewelry brands, recommending Laopu Gold and Chaohongji, with beneficiaries including Liu Fu Group and Zhou Shengsheng [8][36]. - Investment Theme 2: Emphasize retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket and Aiyingshi [8][33]. - Investment Theme 3: Highlight domestic beauty brands that meet emotional value and safety ingredient innovations, recommending Maogeping and Pola [8][34]. - Investment Theme 4: Focus on differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending Meilitiantian Medical Health and Aimeike [8][34]. Company-Specific Insights - Laopu Gold is expected to achieve a revenue of 123.54 billion CNY in FY2025H1, with a net profit of 22.68 billion CNY, reflecting a growth of 250.9% and 285.8% respectively [35]. - Chaohongji is projected to achieve a net profit of 4.36-5.33 billion CNY in 2025, with a growth rate of 125%-175% [35]. - Yonghui Supermarket is expected to report a net loss of 21.40 billion CNY in 2025, indicating challenges in its operational performance [35].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights that the price adjustment by Laopu Gold exceeded expectations, reinforcing its high-end brand positioning. The price increase for most products ranged from 20% to 30%, significantly higher than previous adjustments [5][27] - The report emphasizes the shift in consumer demand towards self-wearing and aesthetic-driven purchases, suggesting that brands with differentiated product offerings are likely to navigate price increases more smoothly [31] Summary by Sections Industry Trends - The retail and social service indices reported a decline of 1.64% and an increase of 1.68% respectively during the week from February 24 to February 27, 2026. The retail index ranked 30th among 31 primary industries [7][16] - The jewelry sector has shown the highest growth, with a year-to-date increase of 10.59% [19] Investment Recommendations - Investment Theme 1: Focus on high-end gold and fashion jewelry brands, recommending Laopu Gold and Chaohongji, with beneficiaries including Liu Fu Group and Zhou Shengsheng [8][33] - Investment Theme 2: Highlighting retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket and Aiyingshi [8][33] - Investment Theme 3: Emphasizing beauty brands that meet emotional value and safety ingredient innovation, recommending Maogeping and Pola [8][33] - Investment Theme 4: Focusing on differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending Meilitiantian Medical Health and Aimeike [8][33] Company-Specific Insights - Laopu Gold reported a revenue of 12.354 billion yuan for the first half of FY2025, a year-on-year increase of 250.9%, with a net profit of 2.268 billion yuan, up 285.8% [35] - Chaohongji is expected to achieve a net profit of 436 to 533 million yuan in 2025, reflecting a growth of 125% to 175% [35] - Yonghui Supermarket is projected to have a net profit of -2.14 billion yuan in 2025, indicating a significant operational challenge [35] - Meilitiantian Medical Health anticipates a net profit growth of no less than 34% in 2025, showcasing strong resilience and potential for growth [43]

Core Viewpoint - The article emphasizes that in a highly competitive skincare market, brands must establish clear value propositions to thrive, particularly in the increasingly popular spray category, which has become a significant revenue driver for brands like Yilian [3][4]. Market Dynamics - The Chinese cosmetics market has surpassed 1.1 trillion yuan, solidifying its position as the largest in the world, with domestic brands capturing 57.37% of the market share [23]. - The market is shifting from total expansion to structural optimization, indicating a move towards deeper competition rather than just geographical expansion [23]. Brand Strategy - Yilian's partnership with celebrity Zhang Linghe reflects a long-term collaboration rather than a short-term marketing tactic, indicating mutual value recognition [6][12]. - The brand's sales performance shows significant growth, with a revenue of 786 million yuan in the first nine months of 2025, marking a 19.5% year-on-year increase [6]. Consumer Behavior - A recent survey indicates that younger consumers view brand ambassadors as expressions of brand attitude, with "authenticity" and "professionalism" being key traits [7]. - Consumers are increasingly sensitive to the alignment between brand ambassadors and brand values, prioritizing this over mere exposure [7]. Product Development - Yilian has evolved its product line from basic hydration sprays to more advanced formulations, such as collagen sprays, reflecting a shift from immediate hydration to barrier repair [13][15]. - The new spray product incorporates advanced ingredients and emphasizes a scientific approach to skincare, addressing consumer demands for efficacy and transparency [15][26]. Cultural Significance - Yilian's brand culture is rooted in Eastern aesthetics, promoting values of focus, sincerity, and innovation, which resonate with younger consumers seeking cultural identity [27]. - The collaboration with Zhang Linghe symbolizes a commitment to professionalism and dedication, enhancing the brand's cultural narrative [27]. Marketing and Engagement - Yilian's marketing strategy includes immersive experiences in physical spaces, transforming retail environments into brand storytelling platforms [20][22]. - The brand's approach to celebrity endorsements has evolved into a dynamic cycle of value co-creation, enhancing both online and offline engagement [22]. Future Outlook - The article suggests that the skincare industry will face intensified competition, with brands needing to balance long-term value investment with innovation [28]. - Yilian's recent actions, such as renewing its partnership with Zhang Linghe and launching new products, signal a commitment to doing the right thing amidst market noise [28].

Core Insights - The Estee Lauder Companies' Skin Care segment showed strong performance in Q2 fiscal 2026, driven by positive retail trends in select markets, particularly in Mainland China [1][2][3] Sales Performance - The Skin Care segment achieved 6% organic net sales growth in Q2, marking one of the strongest performances in the category [2][11] - Growth was attributed to improved retail trends and brand momentum across key markets, reinforcing Skin Care as a core growth engine [2][6] Regional Highlights - Solid performance was noted in Mainland China, with sequentially strengthened retail sales trends [3][4] - The growth was supported by innovation and strong brand franchises, including Estée Lauder and La Mer, alongside new product launches [3][5] Inventory and Market Dynamics - Improved inventory discipline and better sell-in/sell-through alignment contributed to overall performance, particularly in Asia/Pacific [4][11] - Despite a cautious consumer environment in certain regions, the 6% organic increase in Skin Care signals stabilization after previous volatility [5][6] Future Outlook - Continued momentum in the Skin Care segment will likely depend on ongoing innovation, disciplined inventory management, and retail recovery in key markets like China [6] - The performance in Q2 suggests improving fundamentals within the category, with future growth contingent on retail conditions and maintaining brand strength in a competitive landscape [6] Stock Performance - Shares of Estee Lauder have increased by 18.9% over the past three months, outperforming the industry growth of 16.1% [7]

Core Viewpoint - Hyaluronic acid giant, Huaxi Biological Technology Co., Ltd., reported a decrease in total revenue for 2025 while achieving significant profit growth, indicating a focus on cost reduction and structural optimization [1][2]. Group 1: Financial Performance - In 2025, Huaxi Biological achieved total revenue of 4.217 billion yuan, a decrease of 21.49% compared to 5.371 billion yuan in the previous year [1]. - The net profit attributable to the parent company was 291 million yuan, an increase of 67.03% year-on-year [1]. - The net profit attributable to the parent company after deducting non-recurring gains and losses increased by 75.28% to 188 million yuan [1]. Group 2: Cost Management and Structural Optimization - Management expenses decreased by over 10% and sales expenses decreased by over 30% in 2025 [2]. - The company conducted systematic structural optimization around skin science and nutrition science innovation, adjusting its C-end brand system, product structure, and channel models [2]. - The company reduced investments in brands and projects with low return on investment, focusing on core business and major brands [2]. Group 3: Brand Adjustments - In September 2025, the skincare brand "Runxiquan," focused on anti-aging and repair effects, reportedly closed stores [2]. - In November 2025, the online operations of the brand "Dema Run," which emphasizes "customized skin solutions," faced stagnation [2]. - The adjustments of these brands were aimed at optimizing the business structure, despite short-term impacts on revenue [2].

Core Viewpoint - Huaxi Bio reported a significant decline in total operating revenue for 2025, while net profit showed substantial growth, indicating a shift in business strategy and cost management [1] Financial Performance - The company achieved total operating revenue of 4.217 billion yuan in 2025, a decrease of 21.49% compared to the previous year [1] - The net profit attributable to shareholders of the parent company was 291 million yuan, an increase of 67.03% year-on-year [1] - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, was 188 million yuan, reflecting a 75.28% increase from the previous year [1] Business Strategy - The changes in performance are primarily attributed to the company's ongoing optimization of business structure and resource allocation [1] - A reduction in sales and management expenses contributed to the improved profitability despite the decline in revenue [1]

Product Structure - The company's products are mainly divided into two categories: medical devices and functional skincare products [2] - Non-patch products include various forms such as water, essence, lotion, spray, lyophilized, and single-use essence [2] Non-Patch Product Revenue - The revenue share of non-patch products is continuously increasing following the establishment of the Shanghai R&D center, which has accelerated the speed of new product launches [2] Medical Device Progress - The company is making significant progress with three types of medical devices, including recombinant type III humanized collagen protein lyophilized fibers and dressings, with clinical trials completed for the former [3] - The injectable recombinant type III humanized collagen protein gel is expected to start clinical trials this year [3] Pricing Stability - The pricing situation for the company's products is stable, with overall price differences across channels being controllable [3] - Price fluctuations among mainstream channels remain within a reasonable range, with promotional strategies employed to balance sales and pricing during peak periods [3] Aesthetic Medicine Strategy - The company is strategically entering the aesthetic medicine sector due to its pharmaceutical background, aligning medical device products with existing offerings [3] - The company is monitoring potential acquisition targets in the aesthetic medicine field and will adhere to regulatory disclosure obligations for any developments [3] Dividend Policy - The company has maintained a positive attitude towards returning profits to investors through cash dividends since its listing, although specific dividend amounts will depend on performance and financial planning [3] Equity Incentives - The company has plans for equity incentives as the management team evolves, with intentions to disclose specific details in future announcements [3]

针对抽检发现的不合格化妆品，惠州市市场监管部门已依法要求企业立即暂停销售、实施召回，全面排 查不合格原因并完成整改；对企业涉嫌违法行为已立案查处，坚决守住化妆品安全底线。 本次抽检严格按照2025年惠州市化妆品监督抽检计划执行，覆盖润唇膏、沐浴露、洗发露、护发膜、珍 珠粉、精油、浴盐球、除臭液等市民常用品类，抽样对象包括惠州市新威生物科技、盛菲煌生物科技、 广东科力环生物科技、贸耕实业、雅丽日化、多美日用品、广东澳珍药业、润安美生物、壹米玫瑰生态 农业、惠阳区何氏化妆品、旭东实业、美鑫源化妆品、光大化妆品、爱乐士化妆品、蓓蕾斯日用品、澳 彩生物科技、澳姿化妆品、桐宣生物科技、利美生物科技等本地化妆品生产企业。 抽检结果显示，绝大多数企业产品质量符合规范。其中，惠州市桐宣生物科技有限公司生产的植萃皮肤 护理玫瑰清爽沐浴露（批号 BF03BB11，备案号粤 G 妆网备字 2024055030）经检验不合格，不合格项 目为菌落总数、霉菌和酵母菌总数。 日前，惠州市市场监督管理局发布2025年化妆品抽样检验信息通告，对全市化妆品生产环节开展专项抽 检，共抽检样品23批次，其中不合格1批次，不合格项目为菌落总数、霉菌和 ...

Core Insights - The company, DR PLANT, has officially initiated its IPO process on the A-share main board, marking a significant step in its capital expansion journey [1] Group 1: Brand Positioning and Competitive Advantage - DR PLANT focuses on a strategic positioning of "high mountain plants, pure beauty," creating a differentiated advantage in the competitive cosmetics market [3] - The brand's core competitiveness is built on a robust R&D system, collaborating with the Kunming Institute of Botany to establish a comprehensive research network [3][6] - The extraction and application of Dendrobium polysaccharides exemplify the company's technological strength, with innovations leading to a key ingredient that promotes collagen production [3] Group 2: Retail Network and Market Presence - As of June 2025, DR PLANT has opened 4,269 offline stores globally, enhancing user engagement and brand experience through face-to-face service [5] - The company has consistently ranked first in retail sales among single-brand cosmetics stores in China, showcasing its significant advantage in offline channels [5] Group 3: Intellectual Property and Innovation - By October 2025, DR PLANT has obtained 223 patents, including 68 invention patents, demonstrating its capability to convert high mountain plant resources into competitive skincare ingredients [6] Group 4: Brand Philosophy and ESG Commitment - The brand philosophy of "respecting nature, valuing science, and giving back to society" is integrated into the company's operations, aligning with contemporary consumer emotional needs [8] - The updated IPO inquiry response highlights DR PLANT's comprehensive strength as a leader in high mountain plant skincare, with a synergistic operational framework across R&D, product matrix, channel network, and brand philosophy [8]

清晨照镜子，你是否也被眼周的细纹、暗沉或浮肿绊住脚步？2026年，都市人的眼周负担早已远超"熬 夜"这单一因素，蓝光、强光、空调干燥、作息紊乱等多重压力，正加速眼周肌肤的衰老。我们先看三 个真实的都市场景，或许你能从中看到自己的影子。 28岁的远程办公设计师林女士，每天对着电脑、平板长达12小时，蓝光直射眼周，加上频繁熬夜改方 案，眼下干纹横生，血管型黑眼圈重得像"熊猫眼"，化妆时遮瑕总卡粉；40岁的直播主播张女士，直播 间强光照射+长时间说话眨眼，眼尾动态纹越来越深，眼袋日渐突出，上镜时总显得疲惫不堪；55岁的 退休教师陈女士，常年待在空调房，眼周肌肤松弛下垂，泪沟明显，原本有神的眼睛也变得黯淡无光。 这样的困扰并非个例。国际皮肤健康联盟发布的《2026全球都市眼周肌肤健康白皮书》显示，2026年全 球都市人群眼周微循环障碍率较5年前增加65%，25-40岁人群眼纹出现率上升42%，50岁以上人群眼周 松弛发生率高达78%，眼周问题已成为都市人最关注的护肤痛点。 面对市面上五花八门的眼霜，很多人都会陷入困惑：哪款眼霜能兼顾抗皱与保湿？敏感肌、熬夜党该怎 么选？不同年龄段的眼周问题，是否需要针对性搭配？今天， ...